Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G E Adams

Showing results (121-130 of 163) with videos related to

Pageof 17
Sort By:
British Journal of Cancer|July 17, 1998
Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic statusD A Beauregard, P E Thelwall, D J Chaplin, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1992
The response of spontaneous and transplantable murine tumors to vasoactive agents measured by 31P magnetic resonance spectroscopyP J Wood, I J Stratford, J M Sansom, et al.
International Journal of Radiation Oncology, Biology, Physics|July 1, 1991
Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in miceS Cole, I J Stratford, J Bowler, et al.
FEBS Letters|June 5, 1989
Induction of tumour hypoxia by a vasoactive agent. A combined NMR and radiobiological studyJ F Dunn, S Frostick, G E Adams, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1992
Assessment of a range of novel nitro-aromatic radiosensitizers and bioreductive drugsE M Fielden, G E Adams, S Cole, et al.
International Journal of Radiation Oncology, Biology, Physics|May 15, 1994
Radiolytic and photochemical reduction of the hypoxic cytotoxin 1,2-dihydro-8-(4-methylpiperazinyl)-4-phenylimidazo [1,2-a] pyrido [3,2-e] pyrazine 5-oxide (RB90740) and a potential mechanism for hypoxia-selective toxicityM A Naylor, B M Sutton, J Nolan, et al.
International Journal of Radiation Biology|January 1, 1994
Manipulation and exploitation of the tumour environment for therapeutic benefitI J Stratford, G E Adams, J C Bremner, et al.
International Journal of Radiation Oncology, Biology, Physics|May 15, 1994
31P MRS to monitor the induction of tumor hypoxia by the modification of the oxygen affinity of hemoglobin using BW 589CR Kalra, J C Bremner, P J Wood, et al.
International Journal of Radiation Oncology, Biology, Physics|June 15, 1994
Modification of metabolism of transplantable and spontaneous murine tumors by the nitric oxide synthase inhibitor, nitro-L-arginineP J Wood, J M Sansom, I J Stratford, et al.
The British Journal of Cancer. Supplement|July 1, 1996
Changes in energy metabolism and X-ray sensitivity in murine tumours by the nitric oxide donor SIN-1P J Wood, J M Sansom, I J Stratford, et al.
Pageof 17

Showing results (121-130 of 163) with videos related to

Sort By:
Pageof 17
British Journal of Cancer|July 17, 1998
Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic statusD A Beauregard, P E Thelwall, D J Chaplin, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1992
The response of spontaneous and transplantable murine tumors to vasoactive agents measured by 31P magnetic resonance spectroscopyP J Wood, I J Stratford, J M Sansom, et al.
International Journal of Radiation Oncology, Biology, Physics|July 1, 1991
Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in miceS Cole, I J Stratford, J Bowler, et al.
FEBS Letters|June 5, 1989
Induction of tumour hypoxia by a vasoactive agent. A combined NMR and radiobiological studyJ F Dunn, S Frostick, G E Adams, et al.
International Journal of Radiation Oncology, Biology, Physics|January 1, 1992
Assessment of a range of novel nitro-aromatic radiosensitizers and bioreductive drugsE M Fielden, G E Adams, S Cole, et al.
International Journal of Radiation Oncology, Biology, Physics|May 15, 1994
Radiolytic and photochemical reduction of the hypoxic cytotoxin 1,2-dihydro-8-(4-methylpiperazinyl)-4-phenylimidazo [1,2-a] pyrido [3,2-e] pyrazine 5-oxide (RB90740) and a potential mechanism for hypoxia-selective toxicityM A Naylor, B M Sutton, J Nolan, et al.
International Journal of Radiation Biology|January 1, 1994
Manipulation and exploitation of the tumour environment for therapeutic benefitI J Stratford, G E Adams, J C Bremner, et al.
International Journal of Radiation Oncology, Biology, Physics|May 15, 1994
31P MRS to monitor the induction of tumor hypoxia by the modification of the oxygen affinity of hemoglobin using BW 589CR Kalra, J C Bremner, P J Wood, et al.
International Journal of Radiation Oncology, Biology, Physics|June 15, 1994
Modification of metabolism of transplantable and spontaneous murine tumors by the nitric oxide synthase inhibitor, nitro-L-arginineP J Wood, J M Sansom, I J Stratford, et al.
The British Journal of Cancer. Supplement|July 1, 1996
Changes in energy metabolism and X-ray sensitivity in murine tumours by the nitric oxide donor SIN-1P J Wood, J M Sansom, I J Stratford, et al.
Pageof 17